Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Research Points to Second Chance for Rejected Antibiotic Candidate

By University of Leeds | December 15, 2017

An antibiotic candidate compound shelved in the 1970s in favour of more worthwhile drugs could be worth a second look, new research has found.

The drug, called pentyl pantothenamide, is able to stop the growth of E. coli but not completely kill the bacteria, so was never taken into clinical use.

The wider class of pantothenamides have broad spectrum activity against many bacteria but only this one particular molecule is much more effective against E. coli. Exactly what it was doing remained a mystery, but now an international team, led by the University of Leeds, has found the answer.

Their findings, published in the journal Biochemistry, open up the possibility of designing new drugs that use the same means to attack E. coli, but in a more effective way.

Lead researcher, Dr Michael Webb from the Astbury Centre and School of Chemistry at the University of Leeds explains: “Fifty years ago there seemed to be plenty of antibiotics to choose from, so the less promising, like pentyl pantothenamide were often put on the back of the shelf.

“With the rise of antibiotic resistance, we no longer have that luxury. However, scientific advances mean we can now look at these drugs in a new way, and – in this case at least – expect to find a way to make them effective in treating bacterial infections.”

The key to the mystery was Vitamin B5, which is used to metabolise energy. Humans – and indeed all mammals – find it in their diet, but bacteria have to make it and a key part of the machinery they use is called the PanDZ complex.

During a Wellcome Trust-funded sabbatical at the National Institute of Genetics in Japan, Dr Webb showed that pentyl pantothenamide targets the PanDZ complex, preventing E. coli from making Vitamin B5 and so starving it of the means to grow and resist the broad spectrum toxicity caused by the whole pantothenamide class.

The team, which also involved scientists from the University of Hamburg, then used X-ray crystallography to map the structure of the complex. They discovered that the antibiotic binds to the bacteria only in the presence of a particular compound which is created by the bacteria using three different enzymes.

The aim now is to find a molecule that can mimic this final compound, as this could strengthen the action of the antibiotic to make it more effective against this and other related disease-causing bacteria such as Klebsiella and Salmonella which also have a PanDZ complex.

Dr Webb added: “An antibiotic that kills E. coli may not be the only option, because if you can stop the bacteria from growing for long enough, then our own immune system can kick in to finish the job. Now we fully understand how pentyl pantothenamide is working, it may be possible to either identify, or create, a more effective version that could be used to treat patients.”.”


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE